ARTICLE | Clinical News
Zadaxin thymosin alpha 1: Began Phase II trial
December 4, 2000 8:00 AM UTC
SciClone Pharmaceuticals Inc. (SCLN), San Mateo, Calif. Product: Zadaxin thymosin alpha 1 Business: Cancer Therapeutic category: Adjunct, Immune modulation Target: T cells and NK cells Description: S...